Equasym XR 30 mg; Retardkapseln Equasym XR 30 mg; Retardkapseln 瑞士 - 法文 - Swissmedic (Swiss Agency for Therapeutic Products)

equasym xr 30 mg; retardkapseln equasym xr 30 mg; retardkapseln

takeda pharma ag - methylphenidati hydrochloridum - equasym xr 30 mg; retardkapseln - methylphenidati hydrochloridum 30 mg, sacchari sphaerae corresp. saccharum 102.3-149.8 mg et maydis amylum, povidonum, hypromellosum, macrogola, ethylcellulosum, dibutylis sebacas, kapselhülle: gelatina, e 132, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, ammoniae solutio 28 per centum, e 171, e 172 (nigrum) pro capsula. - adh, tdah - synthetika

Elaprase 2 mg/ml Infusionskonzentrat 瑞士 - 法文 - Swissmedic (Swiss Agency for Therapeutic Products)

elaprase 2 mg/ml infusionskonzentrat

takeda pharma ag - idursulfasum - infusionskonzentrat - idursulfasum 2 mg, natrii chloridum, dinatrii phosphas heptahydricus, natrii dihydrogenophosphas monohydricus, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.7 mg. - traitement à long terme des patients avec-le syndrome de hunter (mucopolysaccharidose de type ii, mps ii) - biotechnologika

Edarbi 20mg Comprimés 瑞士 - 法文 - Swissmedic (Swiss Agency for Therapeutic Products)

edarbi 20mg comprimés

takeda pharma ag - azilsartanum medoxomilum - comprimés - azilsartanum medoxomilum 20 mg ut azilsartanum medoxomilum kalicum 21.34 mg, mannitolum, acidum fumaricum, natrii hydroxidum, hydroxypropylcellulosum, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, pro compresso, natrium 0.80 mg. - essentielle hypertonie - synthetika

Edarbi 40mg Comprimés 瑞士 - 法文 - Swissmedic (Swiss Agency for Therapeutic Products)

edarbi 40mg comprimés

takeda pharma ag - azilsartanum medoxomilum - comprimés - azilsartanum medoxomilum 40 mg ut azilsartanum medoxomilum kalicum 42.68 mg, mannitolum, acidum fumaricum, natrii hydroxidum, hydroxypropylcellulosum, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, pro compresso, natrium 1.60 mg. - essentielle hypertonie - synthetika

Edarbi 80mg Comprimés 瑞士 - 法文 - Swissmedic (Swiss Agency for Therapeutic Products)

edarbi 80mg comprimés

takeda pharma ag - azilsartanum medoxomilum - comprimés - azilsartanum medoxomilum 80 mg ut azilsartanum medoxomilum kalicum 85.36 mg, mannitolum, acidum fumaricum, natrii hydroxidum, hydroxypropylcellulosum, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, pro compresso, natrium 3.20 mg. - essentielle hypertonie - synthetika

Intuniv 1 mg Retardtabletten 瑞士 - 法文 - Swissmedic (Swiss Agency for Therapeutic Products)

intuniv 1 mg retardtabletten

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 1 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.03570261 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 23.59 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika

Intuniv 2 mg Retardtabletten 瑞士 - 法文 - Swissmedic (Swiss Agency for Therapeutic Products)

intuniv 2 mg retardtabletten

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 2 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.071402 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 47.18 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika

Intuniv 3 mg Retardtabletten 瑞士 - 法文 - Swissmedic (Swiss Agency for Therapeutic Products)

intuniv 3 mg retardtabletten

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 3 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.04073661 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 39.80 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, e 132, e 172 (flavum), pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika

Intuniv 4 mg Retardtabletten 瑞士 - 法文 - Swissmedic (Swiss Agency for Therapeutic Products)

intuniv 4 mg retardtabletten

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 4 mg ut guanfacini hydrochloridum 4.56 mg, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.054581 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 53.07 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, e 132, e 172 (flavum), pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika

Alunbrig 欧盟 - 法文 - EMA (European Medicines Agency)

alunbrig

takeda pharma a/s - brigatinib - carcinome, poumon non à petites cellules - agents antinéoplasiques - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.